Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) have progressed to first-line monotherapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Wenjing, Zhao, Mingfang, Wang, Ruoyu, Li, Heming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444356/
https://www.ncbi.nlm.nih.gov/pubmed/34526102
http://dx.doi.org/10.1186/s13045-021-01161-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444356/
https://www.ncbi.nlm.nih.gov/pubmed/34526102
http://dx.doi.org/10.1186/s13045-021-01161-8

Ejemplares similares